Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $30.00

Eton Pharmaceuticals (NASDAQ:ETON) had its price target upped by Craig Hallum from $29.00 to $30.00 in a research note issued to investors on Tuesday,Benzinga reports. Craig Hallum currently has a buy rating on the stock.

ETON has been the subject of several other research reports. HC Wainwright raised their price target on Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a report on Monday. Wall Street Zen lowered shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Zacks Research raised shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $31.00.

Eton Pharmaceuticals Stock Down 1.7%

Shares of ETON stock opened at $17.24 on Tuesday. The company’s fifty day simple moving average is $16.23 and its two-hundred day simple moving average is $17.24. Eton Pharmaceuticals has a 52 week low of $11.09 and a 52 week high of $23.00. The stock has a market cap of $462.38 million, a P/E ratio of -68.96 and a beta of 1.19. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19.

Institutional Trading of Eton Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Deutsche Bank AG grew its stake in shares of Eton Pharmaceuticals by 4.9% during the fourth quarter. Deutsche Bank AG now owns 18,249 shares of the company’s stock valued at $309,000 after buying an additional 850 shares during the last quarter. Intech Investment Management LLC boosted its holdings in Eton Pharmaceuticals by 11.1% during the 4th quarter. Intech Investment Management LLC now owns 12,421 shares of the company’s stock valued at $210,000 after acquiring an additional 1,244 shares during the period. Man Group plc grew its position in Eton Pharmaceuticals by 6.0% in the 2nd quarter. Man Group plc now owns 23,754 shares of the company’s stock valued at $338,000 after acquiring an additional 1,350 shares during the last quarter. State of Alaska Department of Revenue bought a new position in Eton Pharmaceuticals in the 3rd quarter valued at $30,000. Finally, Quarry LP purchased a new stake in Eton Pharmaceuticals in the third quarter worth $37,000. Institutional investors own 27.86% of the company’s stock.

Key Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $37 and lifted multiple quarterly and multi‑year EPS forecasts (including FY2026–FY2029 and longer‑term outlook), maintaining a Buy rating — a bullish signal for longer‑term revenue/profit expectations. HC Wainwright Boosts Eton Pharmaceuticals (NASDAQ:ETON) Price Target to $37.00
• Neutral Sentiment: Reported short‑interest data for early March shows effectively zero short interest (data appears inconsistent/placeholder), so short squeezes or heavy short selling are not an immediate explanatory factor for today’s move.
• Neutral Sentiment: Trading context: intraday volume was above average and the stock is near its 200‑day moving average — this can amplify moves on news or positioning changes as investors adjust exposure.
• Negative Sentiment: HC Wainwright trimmed its Q1 2026 EPS estimate (from $0.23 to $0.20), a near‑term downgrade that could explain some downward pressure despite the longer‑term upgrades. Eton Pharmaceuticals on MarketBeat

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.